Clinical Trial


Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis


Brief description

This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.

Detailed Description

This is a 55-week, randomized, double-blind, active-control, parallel group, multicenter, global study in subjects with active, moderate to severe, chronic PsO. The study will consist of 24 weeks of administration of blinded study drug, divided into Treatment Period 1 and Treatment Period 2, then 23 weeks of administration of open-label CHS-1420 and a Follow-up visit 8 weeks after the last dose. Subjects who meet inclusion/exclusion criteria will be stratified by body mass index (BMI), and age and randomized 1:1 to receive CHS-1420 or Humira in Treatment Period 1. Subjects assigned to CHS-1420 will continue to receive CHS-1420 in Period 2. Subjects assigned to Humira in Period 1 will be randomly assigned (1:1) to either continue with Humira in Treatment Period 2 or to switch to CHS-1420 in Treatment Period 2. All subjects will receive open label CHS-1420 in Treatment Period 3.

Keywords

  •   Plaque Psoriasis

Sponsored By

Coherus Biosciences, Inc.

Unique Study ID

NCT02489227

Investigators and Research Sites Near You - Found( 3 )

No Investigator Listed

Sanofi
85013, Phoenix, Arizona, United States
Distance from Current Trial is 0 miles

No Investigator Listed

Takeda
85013, Phoenix, Arizona, United States
Distance from Current Trial is 0 miles

Sanjay Shah, MD

Global Blood Therapeutics
85016, Phoenix, Arizona, United States
Distance from Current Trial is 0 miles
View All